Anti-SARS-CoV-2 antibodies seroprevalence among patients submitted to treatment for tuberculosis in Rio de Janeiro, Brazil: a cross-sectional study

  1. Karen Machado Gomes
  2. Suzanne Pereira Leite
  3. Maria Helena Vieira Moutinho
  4. Thatiana Alfena de Souza
  5. Rita de Cássia Batista
  6. Luiz Claudio Motta de Oliveira
  7. Paulo Redner
  8. Jesus Pais Ramos
  9. Fatima Maria Gomes da Rocha
  10. Gisele Pinto de Oliveira
  11. Antônio Teva
  12. Fernando do Couto Motta
  13. Marilda Agudo Mendonça Teixeira de Siqueira
  14. Rafael Silva Duarte
  15. Francisco Inácio Pinkusfeld Monteir Bastos
  16. Paulo Victor de Sousa Viana
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Due to tuberculosis (TB) patients’ pulmonary damages, some authors believe that a SARS-CoV-2 coinfection may result in unfavorable outcomes. A cross-sectional anti-SARS-CoV-2 antibodies seroprevalence study was conducted at a TB treatment tertiary referral unit in Rio de Janeiro, Brazil, to estimate the proportion (in %) of TB patients exposed to the new coronavirus and their main outcomes. Of 83 patients undergoing TB treatment, 26.5% have already been infected by the new coronavirus. Most patients were asymptomatic (69%) or had mild COVID-19 cases (31%). Only one patient required hospitalization. Among the symptoms and signs presented, the most frequently reported were: fever, headache, and myalgia. People with less education and less purchasing power seemed to had been more exposed to SARS-CoV-2.

Related articles

Related articles are currently not available for this article.